Home Infusion Therapy Market share forecast to reach $28bn by 2024: Global Market Insights Inc. Over the recent years, home infusion therapy market has witnessed an expeditious growth trend, courtesy – the exemplary advancements in medical technology space. The rise of innovative technological solutions has been facilitated seamlessly by a robust regulatory framework, which has further positively impacted the competitive prospects among the prominent industry players. Furthermore, the technological progress being observed in infusion pumps, which are increasingly being utilized in medical setups such as hospitals, nursing homes, and homecare, shall propel the home infusion therapy industry in the upcoming years. To cite the most recent development in this industry, one of the prominent medical device manufacturers, Smiths Medical, has recently unveiled an upgraded version of ambulatory infusion pump, which has now been equipped with wireless communication linked to PharmGuard Server software that allows clinicians to securely employ software updates, track the pump locations, manage the performance of pumps remotely and download data reports. Such dynamic and smart product innovations with high-degree of accuracy and precision are set to assist the swift expansion of home infusion therapy market. As per a report published by Global Market Insights Inc., home infusion therapy market size witnessed a valuation of over $14 Billion in 2016.
Home infusion therapy, in the recent past, has gained renowned traction across the globe, as it has continuously been contemplated as the most appropriate alternative for people suffering from chronic diseases. Concurrently, the significant rise in the geriatric population around the globe, who are vulnerable to chronic diseases such as cancer, diabetes, cardiovascular ailments, and respiratory disorders have contributed to the growth of home infusion therapy market in an unprecedented way. Speaking of the application landscape of home infusion therapy industry, the predominant ones include hydration therapy, chemotherapy, anti-infectives, enteral nutrition, specialty pharmaceuticals, among others. Out of these, anti-infectives contributed to a sizeable revenue share in 2016. The investment in anti-infectives has been stagnant in the last few years, as no new anti-infective has been formed for community-acquired bacterial pneumonia (CABP) in the last 15 years. This trend is set to change in the near future, as a leading Irish biopharma Nabriva Therapeutics plc has succeeded in the initial phases of evaluating a new anti-infective to treat CABP. Such encouraging initiatives undertaken by industry players in anti-biotics and other applications are bound to aid the home infusion therapy market expansion. 1|Page